Company: RNAC
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001453687-25-000120
Chunk: 25

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 25
---
890)Other income (expense), net— 250 (5)1,050 Net loss$(35,902)$(24,183)$(37,726)$(67,171)Other comprehensive (loss) income:Foreign currency translation adjustment(10)(15)34 (6)Total comprehensive loss$(35,912)$(24,198)$(37,692)$(67,177)Net loss(35,902)(24,183)(37,726)(67,171)Net loss per share allocable to common stockholders:Basic and diluted$(1.38)$(1.13)$(1.45)$(4.61)Weighted-average common shares outstanding:Basic and diluted26,002,892 21,471,408 25,962,302 14,561,613 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

6

Table of Contents 

Cartesian Therapeutics, Inc. and Subsidiaries

Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Deficit

(Amounts in thousands, except share data)

 Series ASeries BAdditional paid-in capitalAccumulated deficitAccumulated other comprehensive lossStockholders’ deficit Preferred StockPreferred StockCommon stock SharesAmountSharesAmountSharesAmountBalance at December 31, 2024120,790.402 $— 437,927 $— 25,767,369 $3 $689,887 $(692,071)$(4,621)$(6,802)Issuance of common stock upon exercise of options— — — — 55,690 — 183 — — 183 Issuance of common stock upon vesting of restricted stock units— — — — 113,042 — — — — — Stock-based compensation expense— — — — — — 2,508 — — 2,508 Currency translation adjustment— — — — — — — — 32 32 Net loss— — — — — — — (17,710)— (17,710)Balance at March 31, 2025120,790.402 $— 437,927 $— 25,936,101 $3 $692,578